Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Beta-Endorphin peptide icon, one bubble per amino acidBeta-Endorphin31 residuesYGGFMTSEKSQTPLVTLFKNAIIKNAYKKGEEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Beta-Endorphin

CognitiveResearch
~20-35 minutes half-life·Injection·4w on / 4w off

Also known as: β-endorphin, beta-EP, β-EP

Thirty-one amino acids, 18 to 33 times more potent than morphine, and your body makes it for free. Beta-endorphin is the strongest pain-killing molecule the human body produces. It floods your system during intense exercise, acute trauma, and childbirth, binding mu-opioid receptors with nanomolar affinity. The catch: injecting it doesn't replicate that experience. Subcutaneous beta-endorphin can't cross the blood-brain barrier, so systemic dosing produces hormonal shifts (LH suppression, prolactin rise) without the CNS analgesia or mood effects people typically want. Researchers still study it to understand endogenous opioid pharmacology, but clinical development was abandoned in the 1990s.

What Is Beta-Endorphin?

Eighteen to thirty-three times the analgesic potency of morphine on a molar basis. That number alone explains why beta-endorphin attracted intense research interest after Choh Hao Li and David Chung first isolated it from camel pituitary glands in 1976 [1].

Beta-endorphin (CAS 60617-12-1) is a 31-amino-acid peptide cleaved from the C-terminal end of pro-opiomelanocortin (POMC), the same precursor protein that gives rise to ACTH and alpha-MSH. The arcuate nucleus of the hypothalamus and the anterior pituitary are the primary production sites. Once released, it binds mu-opioid receptors with a Ki of roughly 1 to 3 nM and also acts at delta-opioid receptors.

In practical terms, your body releases beta-endorphin during intense exercise, acute pain, physical trauma, and labor. Plasma levels rise. A 1984 review linked that rise to the "runner's high" but found it unresolved whether blood levels climb enough to change mood [2]. Beyond pain modulation, it influences immune function by modulating natural killer cell activity, regulates appetite through hypothalamic feeding circuits, and participates in reward pathways that overlap with those activated by exogenous opioids.

The clinical trajectory peaked in the early 1980s. Foley and colleagues administered 5 to 10 mg IV to cancer pain patients and documented clear analgesia [3]. One early clinical study showed 3 mg intrathecal produced analgesia lasting roughly 33 hours. Then research stopped. Rapid enzymatic degradation, blood-brain barrier impermeability from systemic routes, and morphine-equivalent dependency risk made synthetic opioids the more practical analgesic path. No modern development pipeline exists. Beta-endorphin today is a research reagent, not a therapeutic candidate.

How Beta-Endorphin Works

Beta-endorphin's primary target is the mu-opioid receptor (MOR). Binding activates Gi/Go proteins and triggers three downstream cascades simultaneously. First, adenylyl cyclase is inhibited, dropping intracellular cAMP. Second, voltage-gated N-type calcium channels close, reducing neurotransmitter release from presynaptic terminals. Third, G-protein-coupled inwardly rectifying potassium channels (GIRKs) open, hyperpolarizing the membrane.

The net result at the spinal level: nociceptive signals get suppressed at dorsal horn synapses. Pain transmission slows.

In the periaqueductal gray and rostral ventromedial medulla, beta-endorphin works through disinhibition. It suppresses tonically active GABAergic interneurons, which releases the brakes on descending serotonergic and noradrenergic analgesic pathways. Pain signals heading up get blocked; pain-suppressing signals heading down get amplified.

Beyond pain, arcuate nucleus POMC neurons release beta-endorphin onto mu-opioid receptors in the ventral tegmental area. This modulates dopaminergic signaling in the nucleus accumbens, contributing to reward processing and stress resilience. The immune system also responds. T-lymphocytes, B-cells, and natural killer cells express mu-opioid receptors; beta-endorphin binding alters cytokine release and cellular immune responses.

Signal termination happens fast. Aminopeptidase N and enkephalinase (neprilysin/CD10) degrade the peptide in plasma within 20 to 35 minutes. That short window is one reason clinical development never progressed.

Beta-Endorphin Benefits

  • Beta-endorphin benefits center on endogenous pain control and neuroendocrine regulation, though exogenous administration remains unvalidated.
  • - Analgesic potency 18 to 33 times greater than morphine on a molar basis, acting through high-affinity mu-opioid receptor binding (Ki ~1 to 3 nM).
  • - Documented stress response modulation in human IV studies, including measurable cortisol and ACTH changes within minutes of administration (Foley 1979)[3].
  • - Linked to exercise-induced mood changes: exercise raises plasma beta-endorphin, but a 1984 review found it unresolved whether that rise is enough to change mood [2].
  • - Immune regulation through mu-opioid receptors on natural killer cells and lymphocytes, modulating cytokine release profiles in preclinical models [4].
  • - Appetite and energy homeostasis regulation via hypothalamic POMC/feeding circuits, positioning it in the broader melanocortin signaling network.
  • - Intrathecal administration produced ~33 hours of sustained analgesia from a single 3 mg dose in one early clinical study, longer than any synthetic opioid at the time.

Beta-Endorphin: Science vs Community Consensus

Science Only
Scientific Evidence
Weak
Based on 9 key studies·Research only

No published SC dosing protocol exists in humans.

Dosing studied: IV: 2.5–10 mg (single dose); Intrathecal: 3 mg (single dose); IV infusion: 0.3–3.0 mcg/kg/min × 30 min (HPA studies). No SC human data.
Read the evidence (key study, limitations)

All clinical exogenous administration used IV or intrathecal routes at milligram-range doses (2.5–10 mg IV; 3 mg intrathecal). Demonstrated acute analgesia, LH suppression, and prolactin rise. SC mcg-range dosing tiers have zero clinical basis. BBB impermeability confirmed: systemic administration does not produce CNS effects.

Key Study

Foley et al. 1979 (PMID 291954): IV 5–10 mg produced analgesia in cancer patients; plasma t½ ~37 min (not 27 min as in pkData)

Limitations

All human exogenous dosing data from 1978–1992; no SC data; full mu-opioid agonist carries morphine-equivalent dependency risk; BBB impermeability limits CNS access from systemic routes; rapid enzymatic degradation (aminopeptidase N, enkephalinase); research pipeline abandoned in 1990s in favour of stable synthetic opioids

Community Experience
None
3.5/5
Based on <5 substantive mentions across all Reddit peptide communities

No self-administration community use documented.

Community dosing: None documented
Read the reports (common issues 5)

Absent from r/Peptides, r/nootropics, r/PeptidesSourceTalk. Not available on the gray market. Prohibitive cost (~$155–$203/mg research-grade reagent; ~$78–$102/day at aggressive tier) prevents practical use.

What users report (0)
    Common issues (5)
    • Full mu-opioid agonist: tolerance, dependence, and withdrawal risk equivalent to morphine
    • SC dosing does not cross BBB; no CNS analgesic or mood effects expected from peripheral injection
    • HPA axis suppression (reduced cortisol, ACTH) with repeated dosing
    • HPG axis suppression (LH↓, testosterone↓/estradiol↓) documented from single IV dose (Reid 1981)
    • Research-reagent-only availability; ~$100/day cost at aggressive tier makes sustained use economically unviable
    Science-Only Evidence

    Historical clinical literature demonstrates clear IV/intrathecal efficacy and hormonal effects. Self-administration community use is effectively nonexistent. SC dosing tiers in the database are unvalidated extrapolations with no clinical counterpart and are explicitly disclaimed as speculative.

    Beta-Endorphin Dosage Guide

    SpeculativeResearch use only; no established injectable dosing protocol in humans
    LevelDose / InjectionFrequency
    Beginner100 mcg
    Moderate250 mcg
    Aggressive500 mcg
    DailyTrack
    Note:

    No subcutaneous dosing protocol has ever been tested in humans. The 100 to 500 mcg SC doses listed are speculative extrapolations with zero clinical basis. Every human study used IV (2.5 to 10 mg) or intrathecal (3 mg) routes, and SC at microgram-range doses sits 10 to 100x below those studied amounts.

    Reconstitution math for reference: a 1 mg vial with 2 mL bacteriostatic water gives you 500 mcg/mL, so 250 mcg equals 0.5 mL (50 units on an insulin syringe). At research-reagent pricing of $155 to $203 per milligram, that single vial costs roughly $155 to $203, and a 500 mcg dose runs about $78 to $102.

    SC injection won't cross the blood-brain barrier. You'll get peripheral hormonal changes (LH drops, prolactin goes up, cortisol shifts) but no CNS analgesia or mood effects. If the goal is boosting the endogenous endorphin system, low-dose naltrexone (1.5 to 4.5 mg nightly) works in the opposite direction and has actual clinical evidence behind it.

    Cycling Protocol

    On Period
    4 weeks
    Off Period
    4 weeks

    Due to limited human clinical data, cycling recommendations are extrapolated from general opioid peptide pharmacology. Conservative protocols suggest a maximum of 4 weeks of intermittent use followed by an equal off period to minimize the risk of tolerance development and HPA axis suppression. Monitoring of mood, pain sensitivity, and endocrine markers is recommended during and after the on-cycle. Abrupt cessation after prolonged use may produce rebound effects.

    Calculate your Beta-Endorphin dose
    Free dosage calculator with syringe visualization

    Or use the universal Peptide Calculator for any peptide.

    Beta-Endorphin Protocols by Goal

    advancedClinical TrialAcute single-dose; analgesic effect 1–4 hours; HPA/HPG changes 1–2 hours post-dose
    Single IV dose (Foley 1979 / Reid 1981)
    Wk Single acute administration
    2.5–10 mg IV · Single dose under clinical supervision · Intravenous

    Expected: Transient analgesia; measurable LH suppression, prolactin rise, and cortisol modulation. CNS effects (mood, reward) not produced via IV at these doses without direct CNS delivery.

    Monitor: Continuous respiratory monitoring (RR, SpO2), blood pressure, pulse oximetry. Naloxone 0.4 mg IV reversal agent required on site.

    How to Use Beta-Endorphin

    1. 1
      Step 1

      Reconstitute the lyophilized powder by adding 2 mL of bacteriostatic water slowly along the vial wall. Swirl gently until dissolved. Do not shake or vortex.

    2. 2
      Step 2

      For a 1 mg vial reconstituted with 2 mL, the concentration is 500 mcg/mL. A 100 mcg dose equals 0.2 mL (20 units on an insulin syringe). A 250 mcg dose equals 0.5 mL (50 units). A 500 mcg dose equals 1.0 mL (100 units, a full syringe).

    3. 3
      Step 3

      For a 2 mg vial reconstituted with 2 mL, the concentration is 1000 mcg/mL. A 100 mcg dose equals 0.1 mL (10 units). A 250 mcg dose equals 0.25 mL (25 units). A 500 mcg dose equals 0.5 mL (50 units).

    4. 4
      Step 4

      Use a 29 to 31 gauge insulin syringe for subcutaneous injection. Inject into abdominal or upper thigh tissue. Rotate injection sites each time.

    5. 5
      Step 5

      No specific timing relative to meals or sleep has been established. All dosing schedules are speculative.

    6. 6
      Store the reconstituted solution at 2 to 8 degrees Celsius

      Use within 14 days. Do not freeze reconstituted solution.

    7. 7
      Step 7

      Pulse oximetry monitoring (SpO2) and respiratory rate checks should accompany every administration, even at SC doses. Naloxone should be accessible.

    Alternative Routes

    Intravenous (IV)

    2.5–10 mg (milligram range); 100% bioavailability; immediate onset; t½ ~37 min

    Foley 1979 (5–10 mg, cancer pain analgesia) and Reid 1981 (2.5 mg, LH/prolactin study). Requires clinical setting, trained staff, resuscitation equipment. Not self-administrable.

    Intrathecal

    3 mg; direct CSF delivery; profound analgesia sustained ~33 hours

    Oyama 1980 data. Completely bypasses BBB limitation of systemic routes. Requires neurosurgical/anaesthesiological administration in hospital setting. Not appropriate outside clinical research.

    Subcutaneous (SC)

    Community-speculated 100–500 mcg; far below mg-range studied doses; SC bioavailability estimated 40–60% but dose magnitude difference is 10–100×

    SC produces peripheral hormonal changes only. BBB impermeability confirmed: CNS analgesic and reward effects require intrathecal or ICV delivery. SC mcg-range doses are 5–100× below any studied IV dose.

    Intranasal

    Unknown; no published data for beta-endorphin

    Beta-endorphin MW ~3,465 Da and hydrophilic character likely limits intranasal CNS bioavailability. Intranasal opioid delivery studied for small-molecule opioids (fentanyl) but not for endogenous opioid peptides of this size.

    Mixing your own vial? Use the Beta-Endorphin reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

    Beta-Endorphin Stacking Protocols

    Works With

    Avoid

    Opioid agonists (morphine, oxycodone, fentanyl, tramadol, codeine)

    Additive mu-opioid receptor activation; potentiated respiratory depression; potentially fatal CNS and respiratory compromise

    Do not combine
    Benzodiazepines / barbiturates / alcohol / z-drugs

    Potentiated CNS and respiratory depression via combined GABAergic and opioid-mediated sedation; significant overdose and death risk

    Do not combine
    MAO inhibitors (phenelzine, tranylcypromine, selegiline)

    Unpredictable potentiation of opioid-mediated CNS effects; potential serotonin syndrome when combined with serotonergic opioid activity

    Do not combine
    SSRIs / SNRIs

    Established serotonin-opioid crosstalk at mu-opioid and serotonergic systems; may alter analgesic efficacy and mood effects unpredictably; potential for serotonin syndrome at higher doses

    Estimated Cost

    Beta-Endorphin Side Effects

    Respiratory depression is the primary acute safety risk. Beta-endorphin is a full mu-opioid agonist. That means the respiratory depression profile is pharmacologically equivalent to morphine, and naloxone must be available during any administration. This is not a peptide with a mild side effect profile.

    The limited human data comes entirely from IV and intrathecal studies conducted between 1978 and 1992. Foley's group [3] administered 5 to 10 mg IV to cancer patients and observed sedation, nausea, and dose-dependent respiratory depression requiring monitoring. Reid's 1981 study [5] documented significant LH suppression and prolactin elevation from a single 2.5 mg IV dose, confirming direct HPG axis effects.

    Published and anticipated side effects from the clinical literature:

    Serious: dose-dependent respiratory depression, CNS depression at higher doses, potential for physical dependence and tolerance with repeated dosing (established mu-opioid pharmacology), opioid-induced hyperalgesia on cessation.

    Common: sedation and drowsiness, nausea and vomiting, constipation and reduced GI motility, miosis, bradycardia, mild hypotension, pruritus at injection site, flushing.

    Hormonal: HPA axis suppression with repeated dosing (reduced cortisol, reduced ACTH). HPG axis suppression (LH suppression, testosterone/estradiol reduction) documented from even a single IV dose. Prolactin elevation via MOR-mediated dopamine suppression.

    There is no community side effect data. Fewer than five substantive threads exist across all Reddit peptide communities. Nobody is self-administering this peptide in practice.

    Individuals with any history of opioid use disorder face raised risk for adverse psychological responses and should not use exogenous beta-endorphin. Concurrent use with benzodiazepines, alcohol, or any CNS depressant creates potentiated respiratory depression risk that can be fatal. Pregnancy and breastfeeding are contraindicated due to potential neuroendocrine effects on the fetus.

    If respiratory rate drops below 12 per minute or SpO2 falls below 94%, stop immediately. Naloxone 0.4 mg IV is the reversal agent. This peptide should never be administered without respiratory monitoring equipment and trained clinical staff.

    Common Issues & Solutions

    No CNS/analgesic or mood effect from SC dosing: expected; beta-endorphin does not cross the BBB from systemic injection. Peripheral SC produces hormonal changes only (LH/prolactin/cortisol). CNS effects require intrathecal or ICV delivery.

    Worsening baseline pain after repeated dosing (opioid-induced hyperalgesia, OIH): MOR downregulation and POMC axis suppression are the pharmacological prediction; dose escalation will accelerate OIH, not resolve it. Discontinue and allow receptor resensitization.

    Signs of HPG axis suppression (low libido, menstrual irregularity, low testosterone/estradiol): opioid-induced hypogonadism (OPIAD); LH suppression documented from a single 2.5 mg IV dose (Reid 1981). Check LH, FSH, sex hormones and hold dosing.

    Signs of HPA axis suppression (fatigue, orthostatic symptoms, low AM cortisol): chronic MOR activation suppresses ACTH and cortisol; monitor AM cortisol and ACTH. Hold dosing if cortisol <10 mcg/dL.

    No established taper protocol: no clinical guidance exists for discontinuing exogenous beta-endorphin after receptor downregulation. Opioid withdrawal management guidelines (SAMHSA) apply if dependence develops; do not abruptly stop after sustained daily use.

    Ask AI about this page

    Ask AI for a second opinion on Beta-Endorphin dosing and side effects

    Contraindications

    • History of opioid use disorder or substance abuse
    • Concurrent use of CNS depressants including benzodiazepines, barbiturates, or alcohol
    • Severe respiratory insufficiency or obstructive pulmonary disease
    • Known hypersensitivity to endogenous opioid peptides or excipients
    • Pregnancy and breastfeeding due to potential neuroendocrine effects on the fetus or infant

    Drug Interactions

    • Opioid agonists and partial agonists (additive respiratory depression and sedation risk)
    • Benzodiazepines and other GABAergic sedatives (potentiated CNS depression)
    • Naloxone and naltrexone (complete antagonism of beta-endorphin effects)
    • MAO inhibitors (potential for unpredictable enhancement of opioid-mediated effects)
    • Corticosteroids (may alter POMC processing and endogenous beta-endorphin levels)
    • Additive mu-opioid receptor activation; potentiated respiratory depression; potentially fatal CNS and respiratory compromise

    Product Quality

    Recommended Monitoring

    TestWhenTarget
    Morning serum cortisolBaseline, week 2 (mid-cycle), end of cycle, and 2 weeks post-cycle10–20 mcg/dL (morning, pre-dose)
    ACTH (plasma)Baseline and end of cycle7–63 pg/mL (morning)
    LH, FSH, total testosterone (males) / LH, FSH, estradiol (females)Baseline and end of cycleLH: 1.5–9.3 mIU/mL; Total T (males): 300–1000 ng/dL; Estradiol (females): cycle-appropriate
    ProlactinBaseline and mid-cycle2–18 ng/mL (males); 2–29 ng/mL (non-pregnant females)
    Respiratory rate and SpO2 (pulse oximetry)During and 30–60 minutes post each administrationRR ≥ 12/min; SpO2 ≥ 95%
    Validated pain sensitivity baseline (e.g., pressure pain threshold or cold pressor test)Baseline, mid-cycle (week 2), and end of cycleNot listed
    Morning serum cortisol

    Chronic MOR activation suppresses CRH → ACTH → cortisol axis; HPA suppression is a primary risk with repeated dosing

    ACTH (plasma)

    Direct marker of pituitary axis suppression; falls before cortisol in early HPA suppression

    LH, FSH, total testosterone (males) / LH, FSH, estradiol (females)

    HPG axis suppression documented from a single 2.5 mg IV dose (Reid 1981 PMID 6262367); chronic dosing expected to cause opioid-induced hypogonadism (OPIAD)

    Prolactin

    Reid 1981 documented significant prolactin elevation from single IV dose via MOR-mediated dopamine suppression; persistent elevation may indicate axis disruption

    Respiratory rate and SpO2 (pulse oximetry)

    Full mu-opioid agonist; dose-dependent respiratory depression is the primary acute safety risk

    Validated pain sensitivity baseline (e.g., pressure pain threshold or cold pressor test)

    Opioid-induced hyperalgesia (OIH) surveillance; worsening pain threshold is the primary indicator of MOR tolerance and OIH progression, warranting discontinuation

    Beta-Endorphin Before and After

    0-15 minutes

    Rapid onset of analgesic and mild euphoric effects following IV administration in preclinical models

    15-60 minutes

    Peak plasma concentration reached; maximal analgesic response and measurable HPA axis modulation

    1-4 hours

    Gradual decline of analgesic effect as peptide is enzymatically degraded; secondary immune modulation effects may persist

    1-2 weeks

    With repeated intermittent dosing, potential cumulative effects on mood and stress response observed in animal models

    4+ weeks

    Risk of tolerance development increases; monitoring for reduced analgesic efficacy and rebound hyperalgesia recommended

    What to Expect

    0 to 30 minutes (Onset, route-dependent): IV administration produces immediate analgesic onset within minutes. SC dosing reaches estimated Cmax around 15 to 30 minutes based on PK extrapolation. Plasma half-life runs about 37 minutes via IV (Foley 1979)[3]. HPA axis changes begin quickly: cortisol drops, ACTH drops, LH falls, and prolactin rises. Side effects at this stage include sedation, nausea, pruritus, mild hypotension, bradycardia, and miosis. No community user data exists for any route.

    30 minutes to 4 hours (Plasma elimination): Aminopeptidase N and enkephalinase break the peptide down rapidly. IV analgesic effects fade by 2 to 4 hours. Intrathecal dosing (3 mg) is the outlier; that route sustained analgesia for roughly 33 hours by bypassing plasma degradation entirely. Hormonal perturbations from IV dosing normalize within 1 to 2 hours. Residual sedation, constipation, and possible rebound dysphoria may follow peptide clearance.

    1 to 2 weeks (Repeated dosing): MOR downregulation begins through beta-arrestin recruitment and receptor internalization. Cumulative HPA and HPG suppression builds. Animal models show reduced endogenous beta-endorphin synthesis with chronic exogenous opioid exposure as arcuate nucleus POMC output drops. Expect diminished analgesic response from the same dose, worsening baseline pain sensitivity, hormonal dysregulation, and mood decline.

    4 or more weeks (Dependence and OIH risk): Opioid-induced hyperalgesia is the pharmacological prediction from established opioid science. Physical dependence equivalent to morphine is anticipated with daily dosing. POMC axis suppression becomes measurable. Abrupt cessation after sustained use is expected to trigger opioid withdrawal: anxiety, sweating, GI distress, insomnia, and pain sensitization. No beta-endorphin-specific long-term human data exists. No taper protocol has been published.

    Detailed Timeline: Science vs Community

    0–30 minutes
    Science

    IV: immediate onset, analgesic within minutes. SC: estimated 15–30 min to Cmax based on PK extrapolation. Plasma t½ ~37 min (IV, Foley 1979). HPA modulation (cortisol↓, ACTH↓) and HPG changes (LH↓, prolactin↑) begin.

    Community

    No community data: no self-administration reports documented.

    30 min – 4 hours
    Science

    Peptide degraded by aminopeptidase N and enkephalinase (neprilysin/CD10). Analgesic effect wanes by ~2–4 hours IV. Intrathecal administration (3 mg): analgesia persists ~33 hours (Oyama 1980). Hormonal perturbations (LH, prolactin, cortisol) normalise within 1–2 hours after IV dosing.

    Community

    No community data.

    1–2 weeks (repeated dosing)
    Science

    MOR downregulation begins with repeated activation (beta-arrestin recruitment, receptor internalisation). Cumulative HPA and HPG suppression. Animal models show reduced endogenous beta-endorphin synthesis with chronic exogenous opioid exposure (arcuate POMC downregulation).

    Community

    No community data.

    4+ weeks
    Science

    Opioid-induced hyperalgesia (OIH) is predicted by established opioid pharmacology. Physical dependence with mu-opioid pharmacology equivalent to morphine anticipated with daily dosing. POMC axis suppression measurable. Abrupt cessation expected to precipitate opioid withdrawal syndrome. No beta-endorphin-specific long-term human data exists.

    Community

    No community data.

    Pharmacokinetics

    Half-Life
    27min
    Bioavailability
    SC: estimated 40-60%; limited by rapid aminopeptidase degradation
    Tmax
    IV: immediate; SC: ~15-30 minutes
    Data Confidence
    moderate

    Source: Foley et al., 1979: plasma elimination studies in humans following IV infusion

    Pharmacokinetics: Active Dose Over Time

    t½ = ~20-35 minutes (plasma); variable CNS half-life

    Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

    Molecular Profile

    Amino Acids
    31
    Sequence
    YGGFMTSEKSQTPLVTLFKNAIIKNAYKKGE
    HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
    Identifiers

    Who Should Consider Beta-Endorphin

    • Pain researchers studying endogenous opioid mechanisms
    • Neuroscientists investigating reward and stress circuitry
    • Neuroendocrinology researchers studying POMC processing
    • Immunologists exploring opioid-immune interactions
    • Exercise physiologists studying runner's high mechanisms

    Related Peptides

    What Changed for Beta-Endorphin

    No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

    Peptide Schedule Research TeamReviewed Apr 8, 20268 Citations

    References

    1. [1]Isolation and structure of beta-endorphin from camel pituitary glands (opens in a new tab)PubMed (opens in a new tab)PubMed
    2. [2]Endorphins and exercise (Sports Med 1984) (opens in a new tab)PubMed (opens in a new tab)Review
    3. [3]beta-Endorphin: analgesic and hormonal effects in humans (Proc Natl Acad Sci U S A 1979) (opens in a new tab)PubMed (opens in a new tab)PubMed
    4. [4]Beta-endorphin modulates immune function: a review (opens in a new tab)PubMed (opens in a new tab)Review
    5. [5]Effects of exogenous beta h-endorphin on pituitary hormone secretion and its disappearance rate in normal human subjects (J Clin Endocrinol Metab 1981) (opens in a new tab)PubMed (opens in a new tab)PubMed

    Related Tools

    Storage & Stability

    Before Reconstitution
    Up to 24 months at -20°C, desiccated, protected from light
    After Reconstitution
    Up to 14 days at 2-8°C; avoid repeated freeze-thaw cycles
    Temperature
    -20°C lyophilized; 2-8°C (36-46°F) reconstituted

    Frequently Asked Questions

    No, not in meaningful amounts. Beta-endorphin is a 31-amino acid, ~3,465 Da hydrophilic peptide that does not cross the blood-brain barrier from systemic circulation. SC injection primarily produces HPA and hormonal changes. LH suppression, prolactin rise, cortisol modulation. Not the reward/mood modulation users typically seek.

    No. Even 100 mcg SC floods peripheral mu-opioid receptors at concentrations far exceeding normal plasma levels (~10–40 pg/mL), creating full opioid pharmacology rather than a physiological endorphin boost. The endogenous system operates at nanomolar CNS concentrations under tight regulatory control; systemic injection bypasses this entirely.

    Yes, this is established opioid pharmacology. Chronic mu-opioid receptor activation causes MOR downregulation and POMC axis suppression, reducing endogenous beta-endorphin synthesis. A daily dosing protocol would be expected to suppress arcuate nucleus POMC output over weeks, worsening baseline pain sensitivity and mood on cessation.

    They work oppositely. LDN (1.5–4.5 mg nightly) transiently blocks MOR, triggering rebound upregulation of endogenous beta-endorphin and receptor sensitivity; a net boost in the endogenous system without dependency risk. Exogenous beta-endorphin floods MOR directly, triggering the same downregulation that reduces natural output over time. LDN has growing clinical evidence; exogenous beta-endorphin has no modern development pipeline.

    Rapid enzymatic degradation required IV or intrathecal delivery; full mu-opioid agonism carries morphine-equivalent dependence risk; and synthetic opioids were cheaper to manufacture. Research pivoted to stable analogs and to understanding the endogenous system rather than therapeutic use of native beta-endorphin.